Healthy Clinical Trial
Official title:
Environments as Smoking Cues: Imaging Brain Substrates, Developing New Treatments
Verified date | January 2017 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overarching goals of this proposal are to 1) identify the network of brain regions
specifically activated by personal smoking environment cues and 2) to evaluate the effects
of exposure to these cues on smoke self-administration and subjective reactivity. The
results of this study will inform the development of novel and more efficacious
cue-exposures therapies targeted at helping smokers quit smoking and will provide novel
mechanism information regarding the influence of environmental context on drug taking.
The investigator hypothesizes that cue-exposure treatments (CETs), in which drug use is
prevented during exposure to drug cues (e.g. lit cigarette) have been of limited efficacy in
part because they have not included cues representative of the contexts in which drug use
occurs. By demonstrating that context cues have a differential and robust influence on brain
and behavioral responses, we will have provided a substantial basis for including such
stimuli in the context of treatment. At the same time, we will have identified novel
mechanisms by which such stimuli promote continued drug use and relapse.
Status | Completed |
Enrollment | 67 |
Est. completion date | July 2014 |
Est. primary completion date | July 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - generally healthy - between the ages of 18 and 55 - smoking an average of 5 cigarettes per day for at least one year - breath CO (carbon monoxide) level > 8 ppm (if = 8 ppm, then NicAlert Strip > 2) - no interest in quitting smoking for the duration of time required for the experiment - right-handed as measured by a three-item scale used in our laboratory - ability to identify 4 personal smoking and 4 personal non-smoking places Exclusion Criteria: - inability to attend all required experimental sessions - significant health problems - use of psychoactive medications - use of smokeless tobacco - current alcohol or drug abuse - use of illegal drugs as measured by urine drug screen - current use of nicotine replacement therapy or other smoking cessation treatment - presence of conditions that would make MRI unsafe (e.g., pacemaker) |
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Signal Change in Functional Magnetic Resonance Imaging (fMRI) BOLD Signal between Personal Environment Pictures Relative to Standard Environment Pictures | During fMRI scanning participants will view pictures of personal and standard smoking and non-smoking environments; and also pictures of smoking-related and non-smoking related objects | following 24 hours of smoking abstinence |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |